Basking Biosciences Doses First Patients in Part B of Phase 2 Stroke Trial, Unlocks $27.5 Million Financing Tranche, and Appoints Julia C. Owens, Ph.D. as Chief Executive Officer
Neucore Bio Awarded Competitive Grant from the U.S. National Science Foundation for Research on Scalability of Exosome-based Therapeutics for Genetic Disease
Neucore Bio Awarded U.S. National Institutes of Health (NIH) STTR Phase I Grant to Pursue Exosome-based Genetic Medicine for Charcot-Marie-Tooth Disease Type 1A (CMT1A)
Neucore Bio Awarded Competitive Grant from the U.S. National Science Foundation for Research on Scalability of Exosome-based Therapeutics for Genetic Disease
